Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Synlogic Inc SYBX

Healthcare Biotechnology
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.


NDAQ:SYBX - Post by User

Synlogic Inc
Bullboard Posts
User Avatar Image
(91)
•••
Post by whytestockson Feb 09, 2024 5:45pm
32 Views
Post# 35873227

Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Sh

Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Sh
BREAKING NEWS: $SYBX Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Shares Nosedive | BenzingaThursday, Synlogic Inc (NASDAQ:SYBX) announced its decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselec...SYBX - Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Shares Nosedive | Benzinga

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities